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Abstract
Objectives To investigate early changes in tumour perfusion parameters by dynamic contrast-enhanced ultrasonography (D-
CEUS) and to identify any correlation with survival and tumour response in patients with metastatic colorectal cancer (CRC)
treated with bevacizumab (B).
Methods Thirty-seven patients randomized to either chemotherapy (C) plus B or C alone were considered for this study. D-
CEUS was performed at baseline and after the first treatment cycle (day 15). Four D-CEUS perfusion parameters were consid-
ered: derived peak intensity (DPI), area under the curve (AUC), slope of wash-in (A) and time to peak intensity (TPI).
Results In patients treated with C plus B, a ≥22.5 % reduction in DPI, ≥20 % increase in TPI and ≥10 % reduction in
AUC were correlated with higher progression-free survival in the C+B arm (p = 0.048, 0.024 and 0.010, respectively)
but not in the C arm. None of the evaluated parameter modifications had a correlation with tumour response or overall
survival.
Conclusions D-CEUS could be useful for detecting and quantifying dynamic changes in tumour vascularity as early as 15 days
after the start of B-based therapy. Although these changes may be predictive of progression-free survival, no correlation with
response or overall survival was found.
Key Points
• D-CEUS showed early changes in liver metastasis perfusion in colorectal cancer.
• A decrease in tumour perfusion was associated with longer progression-free survival.
• The decrease in perfusion was not correlated with higher overall survival.
Keywords Metastatic colorectal cancer . Bevacizumab . Dynamic contrast-enhanced ultrasonography . Tumour angiogenesis .
Early prediction
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DCE-MRI Dynamic contrast-enhanced magnetic
resonance imaging
D-CEUS Dynamic contrast-enhanced ultrasonography
DPI Derived peak intensity
ECOG Eastern Cooperative Oncology Group
EFSUMB European Federation of Societies for
Ultrasound in Medicine and Biology
FOLFOX Folinic acid, 5-fluorouracil and oxaliplatin
FOLFIRI Folinic acid, 5-fluorouracil and irinotecan
5-FU 5-Fluorouracil
ITACa Italian Trial in Advanced Colorectal Cancer




MTT Mean transit time
OS Overall survival
PD Progressive disease
PET Positron emission tomography
PFS Progression-free survival
PS Performance status
rBF Relative blood flow
rBV Relative blood volume
RECIST Response Evaluation Criteria in Solid Tumors
ROC Receiver operating characteristic
ROI Region of interest
TPI Time to peak intensity
V0 Initial intensity value
VEGF Vascular endothelial growth factor
Vmax Maximal intensity value
XELIRI Capecitabine and irinotecan
XELOX Capecitabine and oxaliplatin
Introduction
Colorectal cancer (CRC) is the third most common cancer and
the fourth most frequent cause of cancer death worldwide [1].
About 25% of CRC patients present with metastatic disease at
diagnosis and show a median overall survival (OS) of about 6
months without specific treatments. The combination of a
fluoropyrimidine with either oxaliplatin (FOLFOX,
XELOX) or irinotecan (FOLFIRI, XELIRI) has been widely
accepted as the standard regimen for the first- and second-line
treatment of metastatic CRC [2]. The addition of targeted
agents has further improved treatment outcomes. In particular,
bevacizumab (B), a humanized antivascular endothelial
growth factor (VEGF) recombinant monoclonal antibody that
inhibits angiogenesis by preventing the binding of VEGF to
its cellular receptors, has been shown to improve survival
when added to first-line chemotherapy (C) [3–5]. Although
B is normally fairly well tolerated, a small number of patients
develop severe adverse events and show no survival benefit.
Early functional evaluation of therapeutic response is essential
to identify those who are more likely to respond, thus sparing
non-responders from unnecessary toxicity and lowering over-
all treatment costs [6].
In recent years some studies have suggested that
antiangiogenic drugs induce changes in tumour structure
(e.g. decreased tumour perfusion or necrosis), resulting in a
therapeutic response before a change in tumour size is ob-
served [7, 8]. Adequate early evaluation of efficacy and re-
sponse to these treatments is difficult because traditional re-
sponse criteria are mainly based on a reduction in tumour size
(Response Evaluation Criteria in Solid Tumors, RECIST) es-
timated with imaging techniques [9, 10].
Several dynamic imaging modalities and mathematical
models have been used to quantify changes in liver
tumour perfusion at an early time-point after the start of
treatment. Various functional imaging tools, including
contrast-enhanced ultrasound (D-CEUS), dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI), dynamic contrast-enhanced computed tomography
(DCE-CT) and positron emission tomography (PET), have
been proposed to evaluate the antiangiogenic effects of
cancer drugs [11–14].
D-CEUS is emerging as a non-invasive and repeatable
technique to measure perfusion and therefore as an attractive
tool for monitoring antiangiogenic treatment response [5, 15].
D-CEUS has numerous advantages over other functional
imaging techniques: the ultrasound contrast agent is ap-
propriate for this type of analysis as it is intravascular and
enables perfusion to be studied in real-time. It is also a
safe (patients are not exposed to ionizing radiation) and
inexpensive method. Semiquantitative perfusion and tu-
mour vascular density such as relative blood volume
(rBV) and relative blood flow (rBF) can be determined
from the time-concentration curve constructed by perfu-
s ion sof tware which represents the kine t ics of
microbubble contrast agent flow through the tumour [16,
17]. Although the accuracy of D-CEUS in microvascular
perfusion assessment and in the evaluation of changes in
tumour perfusion after therapy has been documented in
both experimental models [18–20] and patients with a
wide range of cancers [6, 21, 22], its impact on clinical
practice remains modest.
The aim of this monocentre, prospective, controlled
clinical trial was to investigate whether significant early
changes in tumour perfusion parameters can be assessed
by D-CEUS in patients with liver metastases from CRC
treated with B-based chemotherapy. The secondary aim
was to correlate potential changes in functional param-
eters with survival and tumour response assessed by
RECIST 1.1. The first 37 eligible patients from the




This was a monocentre, prospective, non-pharmacologi-
cal, controlled clinical trial in CRC patients recruited from
the ITACa study. The primary aim was to investigate
whether significant early changes in tumour perfusion pa-
rameters can be assessed by D-CEUS. The secondary aim
was to correlate changes in functional parameters with
survival and tumour response.
Patients
Thirty-seven consecutive patients enrolled onto the ITACa
(Italian Trial in Advanced Colorectal Cancer) trial (EudraCT
no. 2007-004539-44 and ClinicalTrials.gov NCT01878422)
from 2009 to 2013 were considered for this study [23].
Inclusion criteria were histologically or cytologically
confirmed CRC and one or more non-resectable liver metas-
tases; age ≥ 18 years and < 70 years; Performance Status
(ECOG) ≤ 2; measurable disease according to RECIST
criteria; estimated life expectancy of at least 12 weeks;
adequate haematological, hepatic and renal function, as
follows: haemoglobin ≥ 9 g/dl, absolute neutrophil count ≥
1,500/μl, platelets ≥ 100,000/μl, total bilirubin ≤ 1.5 × upper
limit of normal (ULN), alkaline phosphatase, aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT) ≤
2.5 × ULN (≤ 5 × ULN in the presence of liver metastases),
serum creatinine ≤ 1.5 × ULN or calculated creatinine clear-
ance > 50 ml/min (calculated on the basis of the standard
Cockcroft-Gault formula). Exclusion criteria comprised con-
traindications to the use of the ultrasound contrast agent; clin-
ically significant cardiovascular or peripheral vascular dis-
ease; uncontrolled hypertension; bleeding diathesis or coagu-
lopathy; pulmonary embolism or any arterial or venous em-
bolism; chronic use of aspirin (> 325 mg/day), other antiplate-
let agents or anticoagulants; proteinuria (if protein > 30 mg/dl
or +1, patients must have ≤ 1 g of protein/24 h) and known
central nervous system metastases.
The study was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. All patients were required to give written in-
formed consent before enrolment. The study was approved
by the Ethics Committee of IRST and the Wide Catchment
Area of Romagna (Area Vasta Romagna).
Treatment
All eligible patients were randomized to receive either C plus
B (arm A) or C alone (arm B). The chosen regimens were
FOLFIRI or FOLFOX4, at the discretion of the clinician, for
both arms. FOLFIRI consisted of irinotecan 180 mg/m2 given
as a 90-min infusion on day 1 added to a standard 5-
fluorouracil (5-FU) + leucovorin (LV) regimen: LV 100 mg/
m2 given as a 2-h infusion followed by bolus 5-FU 400mg/m2
and a 22-h infusion of 5-FU 600 mg/m2 on days 1–2 every 2
weeks. FOLFOX4 consisted of the same 5-FU+LV regimen,
with the addition of oxaliplatin 85 mg/m2 as a 2-h infusion on
day 1. B was administered as a 30- to 90-min intravenous
infusion at a dose of 5 mg/kg on day 1 of each 2-week cycle.
Treatment continued until disease progression (PD), with-
drawal of consent or unacceptable toxicity, whichever came
first. All patients were followed until death.
Dynamic contrast-enhanced ultrasonography
D-CEUS scans were carried out at baseline (day 0) and after the
first cycle of treatment (day 15). Two different radiologists (with
more than 5 years’ experience in D-CEUS) performed the ultra-
sound independently using the iU22 vision 2008 medical ultra-
sound system (Philips Healthcare, Best, The Netherlands) and a
convex-array abdominal C5-2-MHz transducer for deep target
lesions or a 12-MHz linear-array probe for shallow targets. D-
CEUS was carried out in two phases. A single target lesion
selected on the basis of size (largest) and site (best acoustic
window for data acquisition) was studied in each patient.
A morphological study was initially made in B-mode so-
nography to identify the best scanning plane and, in patients
with multiple liver metastases, the largest lesion detectable
(‘target lesion’). The second phase began after 2.4 ml of a
second-generation ultrasound contrast agent (SonoVue, Bracco,
Milan, Italy) was injected as a peripheral intravenous bolus and
immediately flushed with 5–10 ml of 0.9 % NaCl solution.
The study of the whole vascular phase was performed in
accordance with the guidelines of the European Federation of
Societies for Ultrasound inMedicine and Biology (EFSUMB)
[24]. In particular, a low mechanical index-technique (MI ≤
.08) and adjusting gain, depth and frame rates (7–14 Hz) were
used to obtain a real-time digital video of 3 min showing all
the steps of contrast enhancement of intratumour vasculariza-
tion. Patients were required to maintain respiratory apnoea for
the entire acquisition time or, when lesions were superficial, to
breathe lightly. Each CEUS scan, including preparation and
execution, took around 20 min.
Assessment of tumour vascularity
A quantification of contrast uptake in the target liver lesion
was performed by advanced ultrasound quantitative analysis
software package QLAB, version 7.0 (Philips Healthcare).
QLAB plug-in enables the mean, median and standard devia-
tion of pixel intensity to be analysed for each frame of the
sequence of images in a specific region of interest (ROI). In
all instances, the ROI was drawn around the entire lesion to be
studied. Exported data contained multiple frames and the
means of pixel intensities were processed in a curve of time/
intensity data, which is related to microbubble concentration.
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Motion artifacts (e.g. breathing) were deleted by automatic
technical readjustments (with a real-time motion compensa-
tion algorithm) or when necessary, manually, and by removing
sampled frames in the post-processing analysis.
The following perfusion parameters provided by Q-lab
time-enhancement intensity curves were used: DPI = derived
peak intensity in decibels (dB), related to maximum curve
intensity value; AUC = area under the curve, which is propor-
tional to regional ‘blood volume’; A = slope of wash-in (in dB
s-1); and TPI = time to peak intensity (in seconds), related to
regional ‘blood flow’ (Fig. 1) [24]. The post-processing anal-
yses were performed by a radiologist with more than 3 years’
experience in D-CEUS.
Assessment of efficacy
Response to treatment was evaluated according to RECIST
1.1 criteria on CT scans (Philips 256-Slice Multi-Detector)
performed before treatment and every 2 months of therapy
thereafter until progression [9, 25]. Patients were classified
as responders (partial or complete response confirmed) or
non-responders (stable or progressive disease confirmed) on
the basis of changes in target lesion diameter). Target lesions
chosen for CT scan evaluation were not necessarily the same
as those used for CEUS as both assessments were performed
by independent and blinded radiologists.
Statistical analysis
This was a monocentre, prospective, non-pharmacological,
controlled clinical trial of CRC patients who took part in the
ITACa study. The first 37 eligible patients from the ITACa
trial were prospectively enrolled onto the present study.
Nominal or ordinal variables were presented as frequencies
and percentages; mean, standard deviation, median and 95 %
confidence intervals (CIs) were calculated for continuous var-
iables. The association between baseline patient characteris-
tics and treatment was evaluated using the Chi-square and
Fisher’s test (for categorical variables) or the Wilcoxon median
test (for continuous variables). Changes in tumour perfu-
sion parameters were calculated as percent changes between
the value of the parameter evaluated on day 15 and the value
on day 0. A non-parametric median test (Wilcoxon) was used to
compare median values and changes in tumour perfusion
parameters between the two treatment arms. Two categories
of patients were defined for each tumour perfusion parameter
according to the best parameter variation cut-off determined
using the ROC curve.
Progression-free survival (PFS) was defined as the time
form random assignment to the first documentation of pro-
gressive disease (per investigator assessment), or death from
any cause or the date of the last tumour evaluation. Overall
survival (OS) was defined as the time interval between ran-
dom assignment and death or last follow-up visit. PFS and OS
were estimated by the Kaplan-Meier method and compared by
the log-rank test (at a significant level of 5 %).
All p values were based on two-sided testing and statistical
analyses were performed using SAS Statistical software ver-
sion 9.4 (SAS Inc., Cary, NC, USA).
Results
Patient characteristics
Thirty-seven consecutive and eligible patients enrolled at our
institute in the ITACa trial were included in the present study.
Twenty had been randomized to the C plus B arm and 17 to
the C arm. Patient baseline characteristics are shown in
Table 1. Patient groups according to treatment arm were all
comparable for age, gender, histology, ECOG Performance
Status, tumour localization, stage at diagnosis, C regimen,
KRAS status and prior cancer therapy. The majority of pa-
tients had ECOG PS 0 (75.7 %), primary tumour localization
in the colon (70.3 %), stage IV disease at diagnosis (83.8 %)
and a KRAS mutation (59.5 %).
Fig. 1 Quantitative features of
contrast-enhanced
ultrasonography. Contrast agent
uptake curves constructed from
raw linear data and after
automatic modeling. dB decibels,
Vmaxmaximal intensity value, TPI
time to peak intensity, DPI
derived peak intensity, V0 initial




D-CEUS parameters by treatment arm (DPI, TPI, AUC
and A) are listed in Table 2. Median values of all eval-
uated parameters at both baseline and on day 15
showed a similar distribution in both arms. The percent
change between the median values of three of the four
evaluated parameters differed significantly (DPI de-
crease, p = 0.041; TPI increase, p = 0.006; and AUC,
p = 0.038).
The distribution of D-CEUS parameters and their modifi-
cation in responders and non-responders is reported in
Table 3. No differences in the distribution of median values
of the parameters between baseline and day 15 emerged in
either arm. Moreover, none of the evaluated parameter ratios
showed a correlation with tumour response.
The correlation between D-CEUS parameter modification
and PFS is shown in Table 4. A ≥ 22.5% reduction in DPI, a ≥
20 % increase in TPI and a ≥ 10 % reduction in AUC were
associated with higher PFS in the C plus B arm (p = 0.048,
0.024 and 0.010, respectively) but not in the C alone arm.
Variations of A were not correlated with PFS in either
treatment arm. None of the evaluated parameter modifications
had an impact on tumour response assessed by CTor survival.
Although OSwas twofold higher in C+B patients showing a ≥
20 % increase in TPI and a ≥ 10 % decreased in AUC, the
finding was not significant (p = 0.097 and 0.231, respectively)
(Table 5).
Discussion
Over the past few years, efforts have been intensified to iden-
tify surrogate markers that predict a response in patients un-
dergoing antiangiogenic treatments. In the present study, a
decrease in tumour vascularization of liver metastases was
observed after only one treatment cycle (15 days after the
start of treatment in CRC patients treated with B; Fig. 2). A
decrease in perfusion was interpreted as a significant reduction
of rBV and rBF in the median percent change between the
value of DPI on day 15 and day 0, a significant decrease in
the median percent change between AUC2 and AUC1, and a
significant increase in the median percent change between
TPI2 and TPI1. This finding was further confirmed by a
Table 1. Patient characteristics
Total (n = 37) C+B (n = 20) C (n = 17)
No. (%) No. (%) No. (%) p
Median age, years (range) 69 (37–83) 71 (37–83) 68 (37–81) 0.460
Gender
Male 21 (56.8) 11 (55.0) 10 (58.8)
Female 16 (43.2) 9 (45.0) 7 (41.2) 0.817
ECOG PS
0 28 (75.7) 16 (80.0) 12 (70.6)
1–2 9 (24.3) 4 (20.0) 5 (29.4) 0.512
Tumour localization
Rectum 11 (29.7) 7 (35.0) 4 (23.5)
Colon 26 (70.3) 13 (65.0) 13 (76.5) 0.453
Stage at diagnosis
I–III 6 (16.2) 2 (10.0) 4 (23.5)
IV 31 (83.8) 18 (90.0) 13 (76.5) 0.272
Chemotherapy regimen
FOLFIRI 12 (32.4) 7 (35.0) 5 (29.4)
FOLFOX4 25 (67.6) 13 (65.0) 12 (70.6) 0.721
KRAS status
Wild type 15 (40.5) 7 (35.0) 8 (47.1)
Mutated 22 (59.5) 13 (65.0) 9 (52.9) 0.463
Prior cancer therapy
Surgery 24 (64.9) 14 (70.0) 10 (58.8) 0.484
Radiotherapy 3 (8.1) 1 (5.0) 2 (11.8) 0.459
Adjuvant chemotherapy 2 (5.4) 0 2 (11.8) 0.552
C chemotherapy, B bevacizumab,ECOGPS, Eastern Cooperative Oncology Group performance status,FOLFIRI
folinic acid, 5-fluorouracil and irinotecan, FOLFOX4 folinic acid, 5-fluorouracil and oxaliplatin
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reversal of these median percent changes in the control group
(Table 2, Fig. 3).
Our findings suggest that D-CEUS could be used for the
quantitative assessment of tumour vascularization in patients
undergoing treatment with antiangiogenic agents according to
guidelines of the European Federation of Societies for
Ultrasound in Medicine and Biology for the clinical practice
of contrast-enhanced ultrasound [26–29]. The early assess-
ment of tumour perfusion would help to optimize tailored
treatment, especially in non-responders, sparing patients who
are not likely to respond from unnecessary toxicity and low-
ering nonessential costs [5]. Tumour response criteria such as
RECIST 1.1 (assessed by CT) have proven limited in
assessing response to antiangiogenic drugs [27, 30], while
PFS and OS, often used to assess treatment efficacy, require
long-term observation.
We found that a change in AUC, DPI and TPI from base-
line to day 15 was only related to improved PFS in C+B
patients. At baseline, there was no significant association be-
tween any of the D-CEUS criteria values and PFS. Of the four
parameters assessed, TPI proved to be the most valuable be-
cause it showed an opposite trend in the control group. The
optimal cut-off value for TPI was an increase of 20 % with
respect to baseline.
Table 3. Median value of D-CEUS parameters by treatment arm and responder status
C+B C
Reponders (n = 11) Non responders (n = 9) Reponders (n = 11) Non responders
(n = 6)
Median value (95 % CI) p Median value (95 % CI) p
DPI1 (day 0) 11.37 (9.61 to17.78) 16.78 (14.86–18.85) 0.269 10.52 (8.25–13.66) 8.30 (5.48–13.53) 0.730
DPI2 (day 15) 7.28 (6.90–8.65) 10.40 (7.19–14.65) 0.654 7.53 (5.11–12.35) 7.84 (5.43–13.57) 0.882
Percent change -14.59 (-16.88–-1.00) -29.11 (-38.02–-12.03) 0.575 -12.28 (-52.33–22.81) 18.42 (-15.14–99.48) 0.657
TPI1 (day 0) 9.16 (5.94–13.61) 11.35 (6.14–16.04) 0.708 13.93 (7.14–15.92) 9.96 (12.23–25.53) 0.227
TPI2 (day 15) 15.21 (9.77–22.61) 12.86 (5.42–20.54) 0.822 18.81 (6.64–22.15) 13.01 (4.81–21.35) 0.265
Percent change 23.74 (6.79–45.82) 7.05 (1.00–28.01) 0.318 -19.80 (-37.44–13.14) -24.06 (-50.71–11.99) 1.000
AUC1 (day 0) 257.38 (183.57–400.23) 302.85 (99.88–548.30) 0.822 262.15 (122.54–530.79) 170.45 (51.75–432.17) 0.265
AUC2 (day 15) 250.31 (166.94–300.41) 235.05 (50.23–456.28) 0.708 175.60 (91.57–433.52) 65.59 (45.54–102.04) 0.405
Percent change -13.80 (-21.87–-1.00) -20.97 (-35.14–-8.22) 0.793 -7.54 (-33.01–12.56) 8.53 (-9.77–41.34) 0.462
A1 (day 0) 234.92 (47.18–569.32) 7.32 (5.21–48.43) 0.212 4.05 (1.45–8.28) 5.88 (6.27–15.29) 0.805
A2 (day 15) 182.19 (15.44–437.77) 4.37 (2.13–16.23) 0.318 3.04 (2.12–5.02) 4.85 (3.65–7.17) 0.805
Percent change -22.45 (-35.36–0.00) -23.14 (-47.79–-2.05) 0.851 -10.74 (-59.04–22.97) -8.86 (-19.31–182.00) 0.805
D-CEUS dynamic contrast-enhanced ultrasonography, C chemotherapy, B bevacizumab, DPI derived peak intensity, TPI time to peak intensity, AUC
area under the curve, A slope of wash-in, CI confidence interval
Table 2. Median value of D-
CEUS parameters by treatment
arm
C+B (n = 20) C (n = 17)
Median value (95 % CI) Median value (95 % CI) p
DP1 (day 0) 11.86 (9.61–16.78) 9.22 (5.48–13.66) 0.181
DP2 (day 15) 8.43 (6.90–14.65) 9.06 (5.11–13.57) 0.957
Percent change -24.03 (-38.02–-1.00) 0.00 (-52.33–99.48) 0.041
TPI1 (day 0) 10.74 (5.94–16.04) 13.56 (7.14–25.53) 0.291
TPI2 (day 15) 12.95 (9.77–18.95) 16.22 (4.81–22.15) 0.899
Percent change 22.22 (1.00–45.82) -19.80 (-50.71–13.14) 0.006
AUC1 (day 0) 274.57 (183.57–548.30) 176.69 (51.75–530.79) 0.260
AUC2 (day 15) 242.71 (166.94–456.28) 159.33 (45.54–433.52) 0.342
Percent change -14.09 (-35.14–-1.00) -6.18 (-33.01–41.34) 0.038
A1 (day 0) 10.46 (5.21–569.32) 3.40 (1.45–15.29) 0.181
A2 (day 15) 4.37 (2.13–437.77) 4.01 (2.12–7.17) 0.505
Percent change -22.79 (-47.79–0.00) -10.74 (-59.04–182.00) 0.099
D-CEUS contrast-enhanced ultrasonography, C chemotherapy, B bevacizumab, DPI derived peak intensity, TPI
time to peak intensity, AUC area under the curve, A slope of wash-in, CI confidence interval
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A recent study by Lassau et al. investigated the role of
some parameters related to rBF as TPI and mean transit time
(MTT) in predicting outcome in metastatic cancer patients
treated with B [31]. Furthermore, a large multicentre cohort
study published by the same group in 2014 reported that a
change in AUC 30 days from baseline was the best predictive
criterion for PFS in patients undergoing antiangiogenic
therapy [32]. Similar results were described by Zocco et al.
[6]. More recently, CEUS with VEGFR2-targeted
microbubbles (BR55) was used to investigate tumour perfu-
sion changes in rats with colorectal carcinoma xenografts
treated with regorafenib. A substantial decrease in AUC was
reported in the treatment group, with no significant changes in
the control group. CEUS parameters were also correlated with
Table 4. Progression-free survival according to D-CEUS parameter changes by treatment arm
C+B C
No. of patients No. of events Median PFS (months) (95 % CI) p No. of patients No. of events Median PFS (months)
(95 % CI)
p
Overall 20 20 8.8 (6.2–10.4) – 17 14 9.5 (4.3–11.9) –
DPI reduction
<–22.5 % 9 9 7.9 (4.9–9.1) 12 9 9.5 (1.0–11.9)
≥–22.5 % 11 11 9.7 (3.5–11.9) 0.048 5 5 10.4 (4.3–18.7) 0.588
TPI increase
<+20.0 % 9 9 7.9 (2.5–9.1) 15 12 9.5 (4.3–11.9)
≥+20.0 % 11 11 9.7 (6.2–11.9) 0.024 2 2 6.2 (1.0–11.4) 0.413
AUC reduction
<–10.0 % 7 7 7.9 (4.9–8.6) 11 9 9.5 (1.0–11.9)
≥–10.0 % 13 13 9.7 (7.2–11.6) 0.010 6 5 10.4 (4.3–18.6) 0.469
A reduction
<–23.0 % 11 11 7.9 (4.9–9.1) 10 8 9.5 (0.6–11.9)
≥–23.0 % 9 9 9.7 (2.5–11.9) 0.381 7 6 10.4 (2.0–18.6) 0.853
C chemotherapy, B bevacizumab, DPI derived peak intensity, TPI time to peak intensity, AUC area under the time-intensity curve, A slope of wash-in,
PFS progression-free survival,
CI confidence interval
Table 5 Overall survival according to D–CEUS parameter changes by treatment arm
C+B C
No. of patients No. of events Median OS (months)
(95 % CI)
p No. of patients No. of events Median OS (months)
(95 % CI)
p
Overall 20 17 24.5 (13.1–35.7) – 17 14 14.4–29.2) –
DPI
<–22.5 % 9 9 28.0 (9.0–36.6) 12 9 25.4 (1.0–42.9)
≥–22.5 % 11 8 24.5 (10.2–42.9) 0.898 5 5 24.5 (14.4–37.3) 0.743
TPI
<+20.0 % 9 9 14.5 (4.7–29.6) 15 11 26.8 (14.4–29.2)
≥+20.0 % 11 8 35.7 (10.2–49.5) 0.097 2 2 12.5 (1.0–24.0) 0.119
AUC
<–10.0 % 7 7 14.5 (9.0–29.6) 11 10 23.1 (1.0–29.2)
≥–10.0 % 13 10 28.8 (13.1–42.9) 0.231 6 5 26.8 (14.4–37.3) 0.666
A
<–23.0 % 11 10 24.5 (9.0–29.6) 10 8 26.8 (0.6–42.9)
≥–23.0 % 9 7 35.7 (4.7–49.5) 0.302 7 6 24.0 (4.3–37.3) 0.800
C chemotherapy, B bevacizumab,DPI derived peak intensity, TPI time to peak intensity,AUC area under the time-intensity curve, A slope of wash-in,OS
overall survival, CI confidence interval
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dynamic contrast-enhanced MRI (DCE-MRI) parameters and
immunohistochemistry (VEGFR2, CD31, Ki-67 and TUNEL
staining) [20]. In our study, the optimal cut-off value
corresponded to a 10 % decrease in the AUC baseline value.
No significant correlations were found between perfusion pa-
rameters and OS or tumour response assessed by CT.
The main limitations of our study were the small number of
patients considered, the lack of a control ROI in normal liver
parenchyma, the fact that we were only able to scan one index
liver lesion per patient rather than different liver metastases,
and the failure to use 3D-CEUS. Of note, it has recently come
to light that dynamic 3D-CEUS is superior to 2D-CEUS in
visualizing the spatial relationship, vascularity and perfusion
patterns of focal liver lesions [33]. Generally speaking, the use
of various methodologies for contrast quantification based on
different software programs has led to disparities in trial
Fig. 2 Representative images of a decrease in tumour vascularity in a
responder patient before (baseline) and after (post-treatment) one cycle
of chemotherapy plus bevacizumab. DPI derived peak intensity, AUC
area under the curve, TPI time to peak intensity, A slope of wash-in,
ROI region of interest (shown as green circles), s seconds, dB decibels
Fig. 3 Representative images of unvaried tumour vascularity in a non-
responder before (baseline) and after (post-treatment) one cycle of che-
motherapy alone. DPI derived peak intensity, AUC area under the curve,
TPI time to peak intensity, A slope of wash-in, ROI region of interest
(shown as red circles), s seconds, dB decibels
Eur Radiol
results, indicating that caution is needed when implementing
findings into clinical practice [34]. Adequate operator experi-
ence in D-CEUS quantification is also essential, together with
a preliminary assessment and validation of equipment and
software used [34].
In conclusion, dynamic ultrasonography could be poten-
tially useful for detecting and quantifying functional changes
in tumour vascularity as early as 15 days after the start of B
therapy in patients with metastatic CRC. These early changes
in tumour perfusion may be predictive of PFS and could
become surrogate measures of the performance of
antiangiogenic agents. Further research on a larger sample
size is needed to confirm our findings.
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